We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 03, 2023

Atezolizumab Plus Bevacizumab as First-Line Treatment for Patients With Metastatic Nonsquamous NSCLC With High Tumor Mutation Burden

JAMA Oncology


Additional Info

JAMA Oncology
Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial
JAMA Oncol 2022 Dec 15;[EPub Ahead of Print], M Provencio, AL Ortega, J Coves-Sarto, V Calvo, R Marsé-Fabregat, M Dómine, M Guirado, E Carcereny, N Fernández, R Álvarez, R Blanco, L León-Mateos, JM Sánchez-Torres, IG Sullivan, M Cobo, A Sánchez-Hernández, B Massuti, B Sierra-Rodero, C Mártinez-Toledo, R Serna-Blasco, A Romero, A Cruz-Bermúdez

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading